Analyst Reco. Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
6.48 ^USD	+2.05%		+2.37%	-23.13%

04-08	Replimune Group Provides Interim Results for Skin Cancer Therapy	MT
03-26	Replimune Group, Inc. Announces Management Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating	02-09	MT
Wedbush Cuts Replimune Group's PT to $14 From $52 After Narrow Complete Response Rate Miss in Phase 2 Trial of Skin Cancer Treatment Candidate; Keeps Outperform Rating	12-06	MT
Barclays Lowers Price Target on Replimune Group to $13 From $50, Keeps Overweight Rating	12-06	MT
JPMorgan Adjusts Replimune Price Target to $38 From $42, Maintains Overweight Rating	11-24	MT
HC Wainwright Adjusts Price Target on Replimune Group to $50 From $51, Keeps Buy Rating	07/08/23	MT
JPMorgan Adjusts Price Target on Replimune to $50 From $38, Maintains Overweight Rating	15/06/23	MT
HC Wainwright Raises Price Target on Replimune Group to $51 From $50, Keeps Buy Rating	05/06/23	MT
Piper Sandler Assumes Replimune Group at Overweight With $44 Price Target	17/04/23	MT
HC Wainwright Adjusts Replimune Group's Price Target to $50 From $48, Maintains Buy Rating	10/02/23	MT
EF Hutton Starts Replimune Group at Buy With $60 Price Target	05/01/23	MT
BMO Capital Adjusts Replimune Group's Price Target to $70 From $40, Keeps Outperform Rating	12/12/22	MT
HC Wainwright Adjusts Price Target on Replimune to $48 From $60, Maintains Buy Rating	04/11/22	MT
BMO Capital Adjusts Replimune Group's Price Target to $40 From $30, Keeps Outperform Rating	14/10/22	MT
SVB Securities Adjusts Replimune Group's Price Target to $30 From $37, Reiterates Outperform Rating	03/10/22	MT
Piper Sandler Trims Replimune Group's Price Target to $43 From $44, Reiterates Overweight Rating	17/08/22	MT
SVB Securities Trims Lowers Replimune Group's Price Target to $37 From $48, Maintains Outperform Rating	05/08/22	MT
Wedbush Adjusts Replimune Group's Price Target to $52 From $59, Keeps Outperform Rating	24/05/22	MT
SVB Securities Trims Replimune Group's Price Target to $48 From $49, Keeps Outperform Rating	20/05/22	MT
JPMorgan Lowers Replimune Group's Price Target to $39 From $47, Maintains Overweight Rating	04/04/22	MT
BMO Capital Adjusts Replimune Group's Price Target to $30 From $51, Keeps Outperform Rating	18/03/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Replimune Group, Inc.

Equities

REPL

US76029N1063

Analyst Reco.

Filters